|Description||ILK-IN-1, a ILK inhibitor, has been found to restrain the tumor cell growth through regulating signaling pathways related to oncogenesis and tumor progression. IC50: 0.6 μM.|
|Synonyms||ILK-IN-1; CHEMBL1830587; GTPL8116; SCHEMBL8536228; BDBM50353484; CS-4936|
|Solubility||10 mM in DMSO|
|Application||ILK-IN-1 is a ILK inhibitor that has been found to restrain the tumor cell growth through regulating signaling pathways related to oncogenesis and tumor progression.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
Firategrast is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous syste...
ATN-161 trifluoroacetate salt
ATN-161 trifluoroacetate salt is a beta integrin antagonist with antitumor activity. It is a five -amino-acid peptide derived from the synergy region of fibrone...
BIO 5192 is a selective and potent inhibitor of integrin α4β1 (Very Late Antigen-4; VLA-4) (Kd < 10 pM) wth selectivity for α4β1 over a range of other integrins...
Zaurategrast is an oral α4-integrin inhibitor. It significantly decreased the capacity of lymphocytes to bind vascular adhesion molecule-1 (VCAM-1) and the expr...
ILK-IN-1, a ILK inhibitor, has been found to restrain the tumor cell growth through regulating signaling pathways related to oncogenesis and tumor progression. ...
Obtustatin is an integrin α1β1 inhibitor with IC50 value of 0.8 nM for α1β1 binding to type IV collagen. Some research shows that it has antitumor efficacy in a...
JNJ26076713 is an orally active alpha V integrin antagonist. It may be a potential therapeutic candidate for the treatment of age-related macular degeneration,p...
BIO 1211 is a selective and high affinity integrin α4β1 (Very Late Antigen 4; VLA-4) inhibitor with 200-fold selectivity for the activated form of α4β1 (KD = 70...
P11 is a potent antagonist of the integrin αvβ3-vitronectin interaction with IC50 value of 25.72 nM.
CWHM 12 demonstrated high potency against all of the five possible β subunit binding partners (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8) in in vitro ligand-binding assay...
GLPG-0187 is a small molecule integrin receptor antagonist (IRA) with nanomolar affinity for the RGD-integrin receptors αvβ1, αvβ3, αvβ5, αvβ6 and α5β1 (IC50s =...
Leukadherin-1, also known as LA1, is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1. Leukadherin-1 suppresses hu...
ALG1001, also known as Luminate, a first-in-class integrin peptide therapy, is an angiogenesis inhibitors and Integrin alpha 5 beta 1 modulator. A study from Jo...
TCS 2314 is an integrin very late antigen-4 (VLA-4; α4β1) antagonist (IC50 = 4.4 nM) that inhibits the activation of inflammatory cells.
SR121566A, a non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, has been shown to block platelet aggregation induced by a wide variety of agonists incl...
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor which can be used to modify the surface of cardiovascular implants such as vascular grafts to p...
Integrin Antagonists 27
Integrin Antagonists 27, as s novel anticancer agent., is a small molecule integrin αvβ3 antagonist.
Cilengitide (TFA salt)
Cilengitide is a cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and ...
Tirofiban hydrochloride monohydrate
Tirofiban is a specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Tirofiban is an antithrombotic used in the treatment of unstable angina...
TC-I 15 is a potent α2β1 integrin inhibitor (IC50 = 12 and 715 nM for the inhibition of human platelet adhesion to type I collagen and for platelets under stati...